Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. 2011

Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.

Tyrosine kinase-2 (Tyk2), a member of the Jak family of kinases, mediates the signals triggered by various cytokines, including type I IFNs, IL-12, and IL-23. In the current study, we investigated the in vivo involvement of Tyk2 in several IL-12/Th1- and IL-23/Th17-mediated models of experimental diseases, including methylated BSA injection-induced footpad thickness, imiquimod-induced psoriasis-like skin inflammation, and dextran sulfate sodium- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis. In these disease models, Tyk2 deficiency influenced the phenotypes in immunity and/or inflammation. Our findings demonstrate a somewhat broader contribution of Tyk2 to immune systems than previously expected and suggest that Tyk2 may represent an important candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D003092 Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. Colitides
D000077271 Imiquimod A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,Aldara,R 837,R-837,S 26308,S-26308,Zyclara,R837
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
May 2014, Hepatology (Baltimore, Md.),
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
November 2010, European journal of immunology,
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
June 2011, Journal of immunology (Baltimore, Md. : 1950),
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
January 2019, Experimental biology and medicine (Maywood, N.J.),
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
March 2018, Haematologica,
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
July 2009, Journal of dental research,
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
April 2023, Journal of immunology (Baltimore, Md. : 1950),
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
October 2013, Cytokine,
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
February 2011, PloS one,
Masayuki Ishizaki, and Toshihiko Akimoto, and Ryuta Muromoto, and Mika Yokoyama, and Yuya Ohshiro, and Yuichi Sekine, and Hiroaki Maeda, and Kazuya Shimoda, and Kenji Oritani, and Tadashi Matsuda
January 1990, Lymphokine research,
Copied contents to your clipboard!